Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
Keywords: جهش EGFR; Lung cancer; Non–small-cell lung cancer; Epidermal growth factor receptor; EGFR mutation; Erlotinib; Gefitinib; Tyrosine kinase inhibitor; L858R; L861Q; G719X; Exon 19 deletion compound; Exon 19 deletion double; Exon 19 deletion complex.